292 related articles for article (PubMed ID: 35781786)
1. Urolithin B suppresses osteoclastogenesis via inhibiting RANKL-induced signalling pathways and attenuating ROS activities.
Qu Z; An H; Feng M; Huang W; Wang D; Zhang Z; Yan L
J Cell Mol Med; 2022 Aug; 26(16):4428-4439. PubMed ID: 35781786
[TBL] [Abstract][Full Text] [Related]
2. Urolithin B suppressed osteoclast activation and reduced bone loss of osteoporosis via inhibiting ERK/NF-κB pathway.
Li Y; Zhuang Q; Tao L; Zheng K; Chen S; Yang Y; Feng C; Wang Z; Shi H; Shi J; Fang Y; Xiao L; Geng D; Wang Z
Cell Prolif; 2022 Oct; 55(10):e13291. PubMed ID: 35708050
[TBL] [Abstract][Full Text] [Related]
3. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
[TBL] [Abstract][Full Text] [Related]
4. A novel RANKL-targeted flavonoid glycoside prevents osteoporosis through inhibiting NFATc1 and reactive oxygen species.
Hong G; Chen Z; Han X; Zhou L; Pang F; Wu R; Shen Y; He X; Hong Z; Li Z; He W; Wei Q
Clin Transl Med; 2021 May; 11(5):e392. PubMed ID: 34047464
[TBL] [Abstract][Full Text] [Related]
5. Picrasidine I from Picrasma Quassioides Suppresses Osteoclastogenesis via Inhibition of RANKL Induced Signaling Pathways and Attenuation of ROS Production.
Kong L; Wang B; Yang X; Guo H; Zhang K; Zhu Z; Liu J; Hao D
Cell Physiol Biochem; 2017; 43(4):1425-1435. PubMed ID: 29017159
[TBL] [Abstract][Full Text] [Related]
6. CRISPR/Cas9 knockout of MTA1 enhanced RANKL-induced osteoclastogenesis in RAW264.7 cells partly via increasing ROS activities.
Feng M; Liu L; Qu Z; Zhang B; Wang Y; Yan L; Kong L
J Cell Mol Med; 2023 Mar; 27(5):701-713. PubMed ID: 36786127
[TBL] [Abstract][Full Text] [Related]
7. GSH attenuates RANKL-induced osteoclast formation in vitro and LPS-induced bone loss in vivo.
Han B; Geng H; Liu L; Wu Z; Wang Y
Biomed Pharmacother; 2020 Aug; 128():110305. PubMed ID: 32485573
[TBL] [Abstract][Full Text] [Related]
8. Specnuezhenide suppresses diabetes-induced bone loss by inhibiting RANKL-induced osteoclastogenesis.
Ye X; Jiang J; Yang J; Yan W; Jiang L; Chen Y
Acta Biochim Biophys Sin (Shanghai); 2022 Aug; 54(8):1080-1089. PubMed ID: 35929595
[TBL] [Abstract][Full Text] [Related]
9. Loureirin B suppresses RANKL-induced osteoclastogenesis and ovariectomized osteoporosis via attenuating NFATc1 and ROS activities.
Liu Y; Wang C; Wang G; Sun Y; Deng Z; Chen L; Chen K; Tickner J; Kenny J; Song D; Zhang Q; Wang H; Chen Z; Zhou C; He W; Xu J
Theranostics; 2019; 9(16):4648-4662. PubMed ID: 31367247
[No Abstract] [Full Text] [Related]
10. Glaucocalyxin A suppresses osteoclastogenesis induced by RANKL and osteoporosis induced by ovariectomy by inhibiting the NF-κB and Akt pathways.
Zhu M; Shan J; Xu H; Xia G; Xu Q; Quan K; Liu X; Dai M
J Ethnopharmacol; 2021 Aug; 276():114176. PubMed ID: 33933570
[TBL] [Abstract][Full Text] [Related]
11. Treatment with hydrogen molecules prevents RANKL-induced osteoclast differentiation associated with inhibition of ROS formation and inactivation of MAPK, AKT and NF-kappa B pathways in murine RAW264.7 cells.
Li DZ; Zhang QX; Dong XX; Li HD; Ma X
J Bone Miner Metab; 2014 Sep; 32(5):494-504. PubMed ID: 24196871
[TBL] [Abstract][Full Text] [Related]
12. Trimethylamine-N-Oxide Promotes Osteoclast Differentiation and Bone Loss via Activating ROS-Dependent NF-κB Signaling Pathway.
Wang N; Hao Y; Fu L
Nutrients; 2022 Sep; 14(19):. PubMed ID: 36235607
[TBL] [Abstract][Full Text] [Related]
13. Sargassum serratifolium attenuates RANKL-induced osteoclast differentiation and oxidative stress through inhibition of NF-κB and activation of the Nrf2/HO-1 signaling pathway.
Kim HJ; Park C; Kim GY; Park EK; Jeon YJ; Kim S; Hwang HJ; Choi YH
Biosci Trends; 2018; 12(3):257-265. PubMed ID: 30012915
[TBL] [Abstract][Full Text] [Related]
14. Ellagic acid blocks RANKL-RANK interaction and suppresses RANKL-induced osteoclastogenesis by inhibiting RANK signaling pathways.
Xu H; Chen F; Liu T; Xu J; Li J; Jiang L; Wang X; Sheng J
Chem Biol Interact; 2020 Nov; 331():109235. PubMed ID: 32971123
[TBL] [Abstract][Full Text] [Related]
15.
Rattajak P; Aroonkesorn A; Smythe C; Wititsuwannakul R; Pitakpornpreecha T
Molecules; 2024 May; 29(9):. PubMed ID: 38731604
[TBL] [Abstract][Full Text] [Related]
16. Sestrin2 inhibits RANKL-induced osteoclastogenesis through AMPK activation and ROS inhibition.
Kim K; Kim JH; Kim I; Seong S; Koh JT; Kim N
Free Radic Biol Med; 2024 Feb; 211():77-88. PubMed ID: 38101586
[TBL] [Abstract][Full Text] [Related]
17. Urolithin A attenuates RANKL-induced osteoclastogenesis by co-regulating the p38 MAPK and Nrf2 signaling pathway.
Wei W; Peng C; Gu R; Yan X; Ye J; Xu Z; Sheng X; Huang G; Guo Y
Eur J Pharmacol; 2022 Apr; 921():174865. PubMed ID: 35231470
[TBL] [Abstract][Full Text] [Related]
18. Nrf2 deficiency induces oxidative stress and promotes RANKL-induced osteoclast differentiation.
Hyeon S; Lee H; Yang Y; Jeong W
Free Radic Biol Med; 2013 Dec; 65():789-799. PubMed ID: 23954472
[TBL] [Abstract][Full Text] [Related]
19. Oxidation derivative of (-)-epigallocatechin-3-gallate (EGCG) inhibits RANKL-induced osteoclastogenesis by suppressing RANK signaling pathways in RAW 264.7 cells.
Xu H; Liu T; Li J; Xu J; Chen F; Hu L; Zhang B; Zi C; Wang X; Sheng J
Biomed Pharmacother; 2019 Oct; 118():109237. PubMed ID: 31376653
[TBL] [Abstract][Full Text] [Related]
20. The Coumarin Derivative 5'-Hydroxy Auraptene Suppresses Osteoclast Differentiation via Inhibiting MAPK and c-Fos/NFATc1 Pathways.
Abdallah BM; Ali EM; Elsawy H; Badr GM; Abdel-Moneim AM; Alzahrani AM
Biomed Res Int; 2019; 2019():9395146. PubMed ID: 31976330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
